Vladimir Tolmachev

Has grant

Uppsala University

Sweden

Research Interests

Explore related searches

Professors in Sweden

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Engineered scaffold proteins for radionuclide tumour targeting

Open Date: 2016-01-01

Close Date:

Grant: Close

Towards personalized treatment of malignant tumours overexpressing receptor tyrosine kinases. Development of novel conjugates for radionuclide imaging and therapy

Open Date: 2015-01-01

Close Date:

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Sophia Hober

Professor

KTH Royal Institute of Technology

SWEDEN

View details

Fredrik Frejd

Professor

Uppsala University

SWEDEN

View details

Anna Orlova

Uppsala University

SWEDEN

View details

Ulrika Rosenström

Uppsala Universitet Farmaceutiska fakulteten

SWEDEN

View details

Jens Sörensen

Professor

Uppsala Universitet Medicinska fakulteten

SWEDEN

View details

Anzhelika Vorobyeva

Uppsala University

SWEDEN

View details

Sara Sophie Rinne

Weill Cornell Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Vladimir Tolmachev

Research Interests

Explore related searches

Contact this professor

Recent Grants

Articles (27)

Preclinical Positron Emission Tomography Imaging of B7–H3 Expression Using Affibody Molecules Labeled with Gallium-68

Targeting of Epithelial Cell Adhesion Molecule-Expressing Malignant Tumors Using an Albumin-Binding Domain-Fused Designed Ankyrin Repeat Protein: Effect of the Molecular Architecture

Impact of Radiometal Chelates on In Vivo Visualization of Immune Checkpoint Protein Using Radiolabeled Affibody Molecules

The Impact of the Injected Mass of the Gastrin-Releasing Peptide Receptor Antagonist on Uptake in Breast Cancer: Lessons from a Phase I Trial of [<sup>99m</sup>Tc]Tc-DB8

Reduction of Negative Charge in Mercaptoacetyl-Based Chelators Influences the Biodistribution of Prostate-Specific Membrane Antigen-Targeting Pseudopeptides Labeled with Technetium-99m

Single-Photon Emission Computer Tomography Imaging of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Cancer Patients Using a Novel Peptide-Based Probe [99mTc]Tc-BQ0413 with Picomolar Affinity to PSMA: A Phase I/II Clinical Study

Influence of Molecular Design on the Tumor Targeting and Biodistribution of PSMA-Binding Tracers Labeled with Technetium-99m

Phase I Clinical Evaluation of Designed Ankyrin Repeat Protein [<sup>99m</sup>Tc]Tc(CO)<sub>3</sub>-(HE)<sub>3</sub>-Ec1 for Visualization of EpCAM-Expressing Lung Cancer

Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy

GRPR-Antagonists Carrying DOTAGA-Chelator via Positively Charged Linkers: Perspectives for Prostate Cancer Theranostics

Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion

Evaluation of Approaches for the Assessment of HER2 Expression in Breast Cancer by Radionuclide Imaging Using the Scaffold Protein [99mTc]Tc-ADAPT6

Structural Basis of Activity of HER2-Targeting Construct Composed of DARPin G3 and Albumin-Binding Domains

Phase I Trial of [<sup>99m</sup>Tc]Tc-maSSS-PEG<sub>2</sub>-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors

Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin–Toxin Fusion in a Pancreatic Cancer Xenograft Model

Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation

Preclinical Characterization of a Stabilized Gastrin-Releasing Peptide Receptor Antagonist for Targeted Cancer Theranostics

Synthesis, <sup>123</sup>I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures

Direct Intra-Patient Comparison of Scaffold Protein-Based Tracers, [99mTc]Tc-ADAPT6 and [99mTc]Tc-(HE)3-G3, for Imaging of HER2-Positive Breast Cancer

The GRPR Antagonist [99mTc]Tc-maSSS-PEG2-RM26 towards Phase I Clinical Trial: Kit Preparation, Characterization and Toxicity

Radionuclide Therapy of HER2-Expressing Xenografts Using [177Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab

Application of the concept of traceability in determining the mechanical properties of metals under static tension on the example of GSO 11854–2021

Possibilities of predicting the HER2 / neu status in a primary tumor in breast cancer patients using <sup>99m</sup>Tc-DARPinG3

Preclinical Evaluation of a Novel High-Affinity Radioligand [99mTc]Tc-BQ0413 Targeting Prostate-Specific Membrane Antigen (PSMA)

The Use of the [99mTc]Tc-DARPinG3 in Assessing Tumor Process in a Patient with Metastatic HER2-Positive Breast Cancer (Clinical Case Report)

A direct comparison of the diagnostic efficacy of alternative scaffoldbased radiopharmaceuticals [<sup>99m</sup>Tc]Tc-ADAPT6 and [<sup>99m</sup>Tc]Tc-(HE)<sub>3</sub>-G3 in patients with HER2-positive breast cancer

Estimation of Uncertainty in Charpy Pendulum Impact Test Using the Reference Material

Collaborators (7)

Sophia Hober

Fredrik Frejd

Anna Orlova

Ulrika Rosenström

Jens Sörensen

Anzhelika Vorobyeva

Sara Sophie Rinne

Make your next move.